Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non–small cell lung cancer patients treated with osimertinib

This publication has 33 references indexed in Scilit:

• In situ Protein Detection for Companion Diagnostics
  Frontiers in Oncology, 2013
• In Situ Analysis of Mutant EGFRs Prevalent in Glioblastoma Multiforme Reveals Aberrant Dimerization, Activation, and Differential Response to Anti-EGFR Targeted Therapy
  Molecular Cancer Research, 2012
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
  The Lancet Oncology, 2012
• In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer
  Breast Cancer Research and Treatment, 2011
• Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
  Nature Reviews Clinical Oncology, 2010
• Cell Signaling by Receptor Tyrosine Kinases
  Cell, 2010
• The HER family and cancer: emerging molecular mechanisms and therapeutic targets
  Trends in Molecular Medicine, 2007
• HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells
  Cancer Research, 2005
• Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
  Journal of Clinical Oncology, 2005
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  PLOS Medicine, 2005